Loading
companiesCompany
AVEO Oncology (LG Chem)
AVEO Oncology is a Boston company that developed tivozanib (Fotivda), a VEGF-receptor blocking pill used in relapsed kidney cancer, and was acquired by LG Chem in 2023. Its one marketed product now faces first-line immunotherapy combinations, and the TiNivo-2 rechallenge trial was negative.
Overview
AVEO Oncology, based in Boston, developed tivozanib and was acquired by LG Chem in 2023. Tivozanib, sold as Fotivda, is used in relapsed renal cell carcinoma, the TiNivo-2 trial of tivozanib as an immunotherapy rechallenge was negative, and ficlatuzumab, an HGF antibody, is in development for head and neck cancer. OnCo links it to renal cell carcinoma and to the tivozanib drug record. Whether a late-line VEGF inhibitor can keep a role as first-line immunotherapy combinations move the goalposts is the open question for its one marketed product. Tivozanib has its own page.
Headquarters
Boston, MA, US
Scorecard
All companies#196of 1244 companies, score 29
- approved products +6
- phase 3 +3
- targets +2
- modalities +4
- regions +3
- registry trials +11
1 approved, 1 in phase 3, 0 earlier, 1 targets, 32 registry studies. Formula on the scorecards page.
Type
Website
ApprovedSmall-molecule kinase inhibitor (VEGFR)
Tivozanib · Fotivda
Tivozanib is a VEGF-receptor pill that hits VEGFR1 to 3 with little off-target kinase activity, so it is better tolerated than other anti-angiogenic pills, though hypertension and fatigue remain common. It is approved for kidney cancer after two or more prior treatments, and its TiNivo-2 trial showed that restarting immunotherapy after failure adds nothing.
Phase 3monoclonal antibody
Ficlatuzumab is an experimental monoclonal antibody from AVEO Pharmaceuticals in phase 3 trials for head and neck squamous cell carcinoma, with its target not yet stated publicly.
Similar pages
cancers
fronts
drugs
Phase 3monoclonal antibody
ApprovedSmall-molecule kinase inhibitor (VEGFR)
Tivozanib · Fotivda